Catanese, B., Heise, M., Chang, A. M., Chandhok, G., Velkoska, E., Luo, C., … Edmonston, D. (2026). Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.0000000995

Catanese, Benjamin, Mark Heise, Anna M. Chang, Gursimran Chandhok, Elena Velkoska, Charles Luo, Glenn M. Chertow, Myles Wolf, Peter Szecsödy, and Daniel Edmonston. “Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial.” Clin J Am Soc Nephrol, February 13, 2026. https://doi.org/10.2215/CJN.0000000995.

Catanese B, Heise M, Chang AM, Chandhok G, Velkoska E, Luo C, et al. Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial. Clin J Am Soc Nephrol. 2026 Feb 13;

Catanese, Benjamin, et al. “Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial.” Clin J Am Soc Nephrol, Feb. 2026. Pubmed, doi:10.2215/CJN.0000000995.

Catanese B, Heise M, Chang AM, Chandhok G, Velkoska E, Luo C, Chertow GM, Wolf M, Szecsödy P, Edmonston D. Effect of Clazakizumab on Neutrophil-Lymphocyte Ratio in Patients Receiving Hemodialysis: Secondary Analysis of the POSIBIL6ESKD Phase 2b Trial. Clin J Am Soc Nephrol. 2026 Feb 13;